<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721500</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0812</org_study_id>
    <secondary_id>PROD-502</secondary_id>
    <nct_id>NCT00721500</nct_id>
  </id_info>
  <brief_title>A Comparison of Two Daily Disposable Contact Lenses.</brief_title>
  <official_title>An Evaluation of the Lens Fit of Narafilcon A Soft Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Visioncare Research Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the clinical fitting performance of a new daily disposable
      contact lens to an existing daily disposable contact lens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Eyes Successfully Fit</measure>
    <time_frame>Within 20 minutes of lens insertion</time_frame>
    <description>Overall lens fit acceptance was assessed by the Investigator based on lens fit alone in a 6-level scale; 0=should not be worn, 1=should not be dispensed although no immediate danger, 2=borderline but unacceptable, 3=minimal acceptable, early review, 4=not perfect but OK to dispense and 5=perfect. Lens fitting responses &gt;2 were considered 'successful fit' while the rest of responses were considered 'unsuccessful fit'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Fit Decentration</measure>
    <time_frame>Within 20 minutes of lens insertion</time_frame>
    <description>Lens centration was assessed in primary gaze, diffuse white light, low-medium magnification, with graticule. Lens fit decentration with respect to visible cornea was measured to nearest 0.1mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Tightness on Cornea With Manual Digit Push Up</measure>
    <time_frame>Within 20 minutes of lens insertion</time_frame>
    <description>Lens tightness on push-up assessed by digital push-up test (gentle push of the lens upward using the lower lid) with eye in primary gaze position and observing ease of push-up and speed of return to original position. Tightness is measured on a 0%-100% continuous scale where 0%=falls from cornea without lid support, 50%=optimum and 100%=no movement.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Refractive Error</condition>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>narafilcon A / etafilcon A - etafilcon A - narafilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>narafilcon A / etafilcon A - narafilcon A - etafilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>narafilcon A - etafilcon A - narafilcon A / etafilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A - narafilcon A - narafilcon A / etafilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A</intervention_name>
    <description>contact lens</description>
    <arm_group_label>narafilcon A / etafilcon A - etafilcon A - narafilcon A</arm_group_label>
    <arm_group_label>narafilcon A / etafilcon A - narafilcon A - etafilcon A</arm_group_label>
    <arm_group_label>narafilcon A - etafilcon A - narafilcon A / etafilcon A</arm_group_label>
    <arm_group_label>etafilcon A - narafilcon A - narafilcon A / etafilcon A</arm_group_label>
    <other_name>1-Day Acuvue Moist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>narafilcon A</intervention_name>
    <description>contact lens</description>
    <arm_group_label>narafilcon A / etafilcon A - etafilcon A - narafilcon A</arm_group_label>
    <arm_group_label>narafilcon A / etafilcon A - narafilcon A - etafilcon A</arm_group_label>
    <arm_group_label>narafilcon A - etafilcon A - narafilcon A / etafilcon A</arm_group_label>
    <arm_group_label>etafilcon A - narafilcon A - narafilcon A / etafilcon A</arm_group_label>
    <other_name>TruEye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  They are of legal age (18 years) and capacity to volunteer.

          -  They understand their rights as a research subject and are willing to sign a Statement
             of Informed Consent.

          -  They are willing and able to follow the protocol.

          -  They would be expected to attain at least 6/9 (20/30) in each eye with the study
             lenses.

          -  They are able to wear contact lenses with a back vertex power of -1.00 to -6.00DS.

          -  They have a maximum of 1.00D of refractive astigmatism (i.e. â‰¤ 1.00 DC).

          -  They have successfully worn contact lenses within six months of starting the study.

        Exclusion Criteria:

          -  They have an ocular disorder which would normally contra-indicate contact lens wear.

          -  They have a systemic disorder which would normally contra-indicate contact lens wear.

          -  They are using any topical medication such as eye drops or ointment.

          -  They are aphakic.

          -  They have had corneal refractive surgery.

          -  They have any corneal distortion resulting from previous hard or rigid lens wear or
             has keratoconus.

          -  They are pregnant or lactating.

          -  They have grade 2 or greater of any of the following ocular surface signs: corneal
             oedema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any
             other abnormality which would normally contraindicate contact lens wear.

          -  They have any infectious disease (e.g. hepatitis) or any immunosuppressive disease
             (e.g. HIV).

          -  They have diabetes.

          -  They have taken part in any other clinical trial or research, within two weeks prior
             to starting this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Visioncare Research Ltd</name>
      <address>
        <city>Farnham</city>
        <state>Surrey</state>
        <zip>GU9 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2008</study_first_submitted>
  <study_first_submitted_qc>July 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2008</study_first_posted>
  <results_first_submitted>May 7, 2010</results_first_submitted>
  <results_first_submitted_qc>February 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2011</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 25 subjects enrolled to the study.</recruitment_details>
      <pre_assignment_details>Subjects were enrolled per inclusion/exclusion criteria and randomized to a study arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Narafilcon A/Etafilcon A - Etafilcon A - Narafilcon A</title>
          <description>First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.</description>
        </group>
        <group group_id="P2">
          <title>Narafilcon A/Etafilcon A - Narafilcon A - Etafilcon A</title>
          <description>First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.</description>
        </group>
        <group group_id="P3">
          <title>Narafilcon A - Etafilcon A - Narafilcon A/Etafilcon A</title>
          <description>First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.</description>
        </group>
        <group group_id="P4">
          <title>Etafilcon A - Narafilcon A - Narafilcon A/Etafilcon A</title>
          <description>First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period One</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period Two</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period Three</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled and completed subjects were included in the baseline summary.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects who enrolled and completed study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Eyes Successfully Fit</title>
        <description>Overall lens fit acceptance was assessed by the Investigator based on lens fit alone in a 6-level scale; 0=should not be worn, 1=should not be dispensed although no immediate danger, 2=borderline but unacceptable, 3=minimal acceptable, early review, 4=not perfect but OK to dispense and 5=perfect. Lens fitting responses &gt;2 were considered 'successful fit' while the rest of responses were considered 'unsuccessful fit'.</description>
        <time_frame>Within 20 minutes of lens insertion</time_frame>
        <population>Participants who were enrolled and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon A (Bilateral)</title>
            <description>narafilcon A contact lens worn in both eyes.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A (Contralateral)</title>
            <description>Narafilcon A worn in either eye.</description>
          </group>
          <group group_id="O3">
            <title>Etafilcon A (Bilateral)</title>
            <description>Etafilcon A contact lens worn in both eyes.</description>
          </group>
          <group group_id="O4">
            <title>Etafilcon A (Contralateral)</title>
            <description>Etafilcon A worn in either eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Eyes Successfully Fit</title>
          <description>Overall lens fit acceptance was assessed by the Investigator based on lens fit alone in a 6-level scale; 0=should not be worn, 1=should not be dispensed although no immediate danger, 2=borderline but unacceptable, 3=minimal acceptable, early review, 4=not perfect but OK to dispense and 5=perfect. Lens fitting responses &gt;2 were considered 'successful fit' while the rest of responses were considered 'unsuccessful fit'.</description>
          <population>Participants who were enrolled and completed the study.</population>
          <units>proportion of participant eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98"/>
                    <measurement group_id="O2" value="0.96"/>
                    <measurement group_id="O3" value="0.96"/>
                    <measurement group_id="O4" value="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Fit Decentration</title>
        <description>Lens centration was assessed in primary gaze, diffuse white light, low-medium magnification, with graticule. Lens fit decentration with respect to visible cornea was measured to nearest 0.1mm.</description>
        <time_frame>Within 20 minutes of lens insertion</time_frame>
        <population>Participants who were enrolled and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon A</title>
            <description>Narafilcon A contact lens worn in both eyes.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A (Contralateral)</title>
            <description>Narafilcon A worn in either eye.</description>
          </group>
          <group group_id="O3">
            <title>Etafilcon A (Bilateral)</title>
            <description>Etafilcon A contact lens worn in both eyes.</description>
          </group>
          <group group_id="O4">
            <title>Etafilcon A (Contralateral)</title>
            <description>Etafilcon A worn in either eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Fit Decentration</title>
          <description>Lens centration was assessed in primary gaze, diffuse white light, low-medium magnification, with graticule. Lens fit decentration with respect to visible cornea was measured to nearest 0.1mm.</description>
          <population>Participants who were enrolled and completed the study.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eye</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.14"/>
                    <measurement group_id="O2" value="0.22" spread="0.16"/>
                    <measurement group_id="O3" value="0.27" spread="0.17"/>
                    <measurement group_id="O4" value="0.27" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Tightness on Cornea With Manual Digit Push Up</title>
        <description>Lens tightness on push-up assessed by digital push-up test (gentle push of the lens upward using the lower lid) with eye in primary gaze position and observing ease of push-up and speed of return to original position. Tightness is measured on a 0%-100% continuous scale where 0%=falls from cornea without lid support, 50%=optimum and 100%=no movement.</description>
        <time_frame>Within 20 minutes of lens insertion</time_frame>
        <population>Participants who were enrolled and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon A (Bilateral)</title>
            <description>Narafilcon A contact lens worn in both eyes.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A (Contralateral)</title>
            <description>Narafilcon A worn in either eye.</description>
          </group>
          <group group_id="O3">
            <title>Etafilcon A (Bilateral)</title>
            <description>Etafilcon A contact lens worn in both eyes.</description>
          </group>
          <group group_id="O4">
            <title>Etafilcon A (Contralateral)</title>
            <description>Etafilcon A worn in either eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Tightness on Cornea With Manual Digit Push Up</title>
          <description>Lens tightness on push-up assessed by digital push-up test (gentle push of the lens upward using the lower lid) with eye in primary gaze position and observing ease of push-up and speed of return to original position. Tightness is measured on a 0%-100% continuous scale where 0%=falls from cornea without lid support, 50%=optimum and 100%=no movement.</description>
          <population>Participants who were enrolled and completed the study.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eye</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="6.3"/>
                    <measurement group_id="O2" value="46.9" spread="5.5"/>
                    <measurement group_id="O3" value="56.3" spread="8.6"/>
                    <measurement group_id="O4" value="58.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Narafilcon A/Etafilcon A - Etafilcon A - Narafilcon A</title>
          <description>First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.</description>
        </group>
        <group group_id="E2">
          <title>Narafilcon A/Etafilcon A - Narafilcon A - Etafilcon A</title>
          <description>First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.</description>
        </group>
        <group group_id="E3">
          <title>Narafilcon A - Etafilcon A - Narafilcon A/Etafilcon A</title>
          <description>First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.</description>
        </group>
        <group group_id="E4">
          <title>Etafilcon A - Narafilcon A - Narafilcon A/Etafilcon A</title>
          <description>First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kurt Moody OD FAOO / Director</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-3088</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

